Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men.

Orkaby AR, Gaziano JM, Djousse L, Driver JA.

J Am Geriatr Soc. 2017 Nov;65(11):2362-2368. doi: 10.1111/jgs.14993. Epub 2017 Sep 11.


Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.

Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS; ALLHAT Collaborative Research Group.

JAMA Intern Med. 2017 Jul 1;177(7):955-965. doi: 10.1001/jamainternmed.2017.1442.


PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T, Mamcarz A, Broncel M, Tomasik T, Rysz J, Jankowska-Zduńczyk A, Hoffman P, Mastalerz-Migas A.

Arch Med Sci. 2017 Feb 1;13(1):1-45. doi: 10.5114/aoms.2017.64712. Epub 2016 Dec 19. No abstract available.


Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence.

Gurwitz JH, Go AS, Fortmann SP.

JAMA. 2016 Nov 15;316(19):1971-1972. doi: 10.1001/jama.2016.15212. No abstract available.


Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials.

Liu HW, Bian SY, Zhu QW, Zhao YX.

J Geriatr Cardiol. 2016 Aug;13(8):693-700.


The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review.

Daniel D, Hardigan P, Jawaid A, Bhandari R, Daniel M.

Cholesterol. 2015;2015:292935. doi: 10.1155/2015/292935. Epub 2015 Nov 4.


Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population.

Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H, Molnar MZ, Reddy U, Amin AN, Kovesdy CP, Kalantar-Zadeh K.

J Am Med Dir Assoc. 2015 Nov 1;16(11):933-9. doi: 10.1016/j.jamda.2015.07.014. Epub 2015 Sep 9. Review.


Statins for primary cardiovascular prevention in the elderly.

Pedro-Botet J, Climent E, Chillarón JJ, Toro R, Benaiges D, Flores-Le Roux JA.

J Geriatr Cardiol. 2015 Jul;12(4):431-8. doi: 10.11909/j.issn.1671-5411.2015.04.016. Review.



Han BH, Weinberger Y, Sutin D.

J Gen Intern Med. 2014 Dec;29(12):1702-6. doi: 10.1007/s11606-014-2959-x.


Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.

Roy S.

N Am J Med Sci. 2014 May;6(5):191-8. doi: 10.4103/1947-2714.132916. Review.


Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Pang J, Chan DC, Watts GF.

World J Diabetes. 2014 Apr 15;5(2):165-75. doi: 10.4239/wjd.v5.i2.165. Review.


Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.

Tsigos C, Bitzur R, Kleinman Y, Cohen H, Cahn A, Brambilla G, Mancia G, Grassi G.

Diabetes Care. 2013 Aug;36 Suppl 2:S292-300. doi: 10.2337/dcS13-2021. Review. No abstract available.


Stereoselective binding of chiral drugs to plasma proteins.

Shen Q, Wang L, Zhou H, Jiang HD, Yu LS, Zeng S.

Acta Pharmacol Sin. 2013 Aug;34(8):998-1006. doi: 10.1038/aps.2013.78. Epub 2013 Jul 15. Review.


Cholesterol and cardiovascular disease in the elderly. Facts and gaps.

Félix-Redondo FJ, Grau M, Fernández-Bergés D.

Aging Dis. 2013 Mar 1;4(3):154-69. Print 2013 Jun.


Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan.

Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K, Ueshima H; Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group.

J Am Heart Assoc. 2012 Oct;1(5):e001974. doi: 10.1161/JAHA.112.001974. Epub 2012 Oct 25.


Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.

Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, Hofman A, Steyerberg EW, Hunink MG.

PLoS Med. 2012;9(12):e1001361. doi: 10.1371/journal.pmed.1001361. Epub 2012 Dec 27.


Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Ridker PM.

Curr Atheroscler Rep. 2013 Jan;15(1):295. doi: 10.1007/s11883-012-0295-3. Review.


Workplace based mindfulness practice and inflammation: a randomized trial.

Malarkey WB, Jarjoura D, Klatt M.

Brain Behav Immun. 2013 Jan;27(1):145-54. doi: 10.1016/j.bbi.2012.10.009. Epub 2012 Oct 16.


Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.

Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.


Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.

Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J.

BMJ. 2012 Jul 12;345:e4535. doi: 10.1136/bmj.e4535.

Supplemental Content

Support Center